Get the Stockscreener App
7.32
4.69%
-0.36
Passage Bio Inc stock is traded at $7.32, with a volume of 65,092.
It is down -4.69% in the last 24 hours and down -7.92% over the past month.
Passage Bio Inc is a genetic medicines company. The company is focused on developing transformative therapies for rare, monogenic CNS disorders. It has pipeline products such as GM1 Gangliosidosis, Frontotemporal dementia, and Krabbe Disease. The Company operates in a single reportable segment, developing and advancing genetic medicines designed to target critical underlying pathology of neurodegenerative diseases.
See More
Previous Close:
$7.68
Open:
$7.71
24h Volume:
65,092
Relative Volume:
1.96
Market Cap:
$23.27M
Revenue:
-
Net Income/Loss:
$-68.80M
P/E Ratio:
-6.2564
EPS:
-1.17
Net Cash Flow:
$-59.06M
1W Performance:
+1.67%
1M Performance:
-7.92%
6M Performance:
+1,753%
1Y Performance:
+1,063%
1-Day Range:
$7.23
$7.91
1-Week Range:
$7.00
$7.91
52-Week Range:
$0.257
$9.00
Passage Bio Inc Stock (PASG) Company Profile
Name
Passage Bio Inc
Sector
Industry
Phone
(267) 866-0312
Address
ONE COMMERCE SQUARE, PHILADELPHIA, PA
Compare PASG with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
PASG
Passage Bio Inc
|
7.32 | 24.41M | 0 | -68.80M | -59.06M | -1.17 |
|
VRTX
Vertex Pharmaceuticals Inc
|
426.00 | 109.11B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
642.25 | 68.50B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
434.07 | 60.25B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
826.28 | 50.39B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
186.23 | 40.44B | 447.02M | -1.18B | -868.57M | -6.1812 |
Passage Bio Inc Stock (PASG) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-29-24 | Resumed | Wedbush | Outperform |
| Sep-03-24 | Initiated | Rodman & Renshaw | Buy |
| Mar-08-22 | Downgrade | JP Morgan | Overweight → Neutral |
| Jan-19-22 | Downgrade | Goldman | Buy → Neutral |
| Jul-01-21 | Initiated | Raymond James | Outperform |
| Jun-15-21 | Initiated | BTIG Research | Buy |
| Mar-04-21 | Upgrade | Goldman | Neutral → Buy |
| Feb-04-21 | Initiated | Guggenheim | Buy |
| Jan-25-21 | Initiated | Wedbush | Outperform |
| Jan-04-21 | Upgrade | JP Morgan | Neutral → Overweight |
| Dec-11-20 | Initiated | Citigroup | Neutral |
| Aug-14-20 | Downgrade | JP Morgan | Overweight → Neutral |
| Jun-25-20 | Downgrade | Goldman | Buy → Neutral |
| Mar-25-20 | Initiated | Chardan Capital Markets | Buy |
| Mar-24-20 | Initiated | Cowen | Outperform |
| Mar-24-20 | Initiated | Goldman | Buy |
| Mar-24-20 | Initiated | JP Morgan | Overweight |
View All
Passage Bio Inc Stock (PASG) Latest News
Market reaction to Passage Bio Inc.’s recent newsTrade Risk Assessment & Verified Swing Trading Watchlists - newser.com
Combining machine learning predictions for Passage Bio Inc.Dollar Strength & Weekly Setup with ROI Potential - newser.com
How Passage Bio Inc. stock reacts to Fed rate cutsJuly 2025 PreEarnings & Stepwise Entry and Exit Trade Signals - newser.com
How to recover losses in Passage Bio Inc. stockStop Loss & Accurate Trade Setup Notifications - newser.com
Why Passage Bio Inc. stock remains a top recommendationJuly 2025 Short Interest & Breakout Confirmation Trade Signals - newser.com
Will Passage Bio Inc. price bounce be sustainableGDP Growth & Fast Gain Stock Trading Tips - newser.com
What momentum shifts mean for Passage Bio Inc.2025 Volatility Report & Verified Entry Point Signals - newser.com
Can Passage Bio Inc. stock attract ESG capital inflows2025 Analyst Calls & Safe Entry Point Alerts - newser.com
Why Passage Bio Inc. is moving todayJuly 2025 Trade Ideas & Long-Term Growth Portfolio Plans - newser.com
Using economic indicators to assess Passage Bio Inc. potentialWeekly Profit Report & Free Daily Entry Point Trade Alerts - newser.com
Passage Bio Inc. stock trendline breakdown2025 Pullback Review & AI Forecasted Entry/Exit Points - newser.com
Is Passage Bio Inc. stock bottoming outJuly 2025 Snapshot & Advanced Swing Trade Entry Plans - newser.com
Applying chart zones and confluence areas to Passage Bio Inc.2025 Biggest Moves & Weekly Watchlist for Hot Stocks - newser.com
Why Passage Bio Inc. stock could rally in 2025Quarterly Profit Report & Stepwise Entry/Exit Trade Alerts - newser.com
Multi asset correlation models including Passage Bio Inc.2025 Institutional Moves & Long Hold Capital Preservation Plans - newser.com
How Passage Bio Inc. stock reacts to global recession fearsJuly 2025 Big Picture & Low Drawdown Trading Techniques - newser.com
Smart tools for monitoring Passage Bio Inc.’s price action2025 Momentum Check & Real-Time Chart Pattern Alerts - newser.com
Ocugen to Announce Third-Quarter 2025 Results and Business Update on November 5 - MyChesCo
Predicting Passage Bio Inc. trend using moving averagesJuly 2025 Analyst Calls & Short-Term High Return Ideas - newser.com
Can you recover from losses in Passage Bio Inc.2025 Market Overview & Precise Buy Zone Tips - newser.com
Ranking Passage Bio Inc. among high performing stocks via toolsWeekly Profit Report & Verified Swing Trading Watchlist - newser.com
Passage Bio Inc Stock (PASG) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.64%
0.35%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):